Guardant Health (GH) Research & Development (2017 - 2026)

Guardant Health has disclosed Research & Development across 10 years of filings, most recently posting $91.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $91.0 million, up 2.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $366.7 million (up 4.04% YoY), and the FY2025 annual result was $364.2 million, up 4.73% from the prior year.
• Research & Development came in at $91.0 million for Q1 2026 at Guardant Health, down from $98.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $106.6 million in Q4 2022 to a low of $81.8 million in Q1 2022.
• The 5-year median for Research & Development is $90.0 million (2025), against an average of $90.8 million.
• Across the five-year window, Research & Development jumped 47.29% in 2022 and declined 15.69% in 2023, its largest moves.
• Guardant Health's Research & Development stood at $106.6 million in 2022, then decreased by 15.69% to $89.9 million in 2023, then grew by 4.1% to $93.5 million in 2024, then rose by 5.05% to $98.3 million in 2025, then fell by 7.35% to $91.0 million in 2026.
• The last three Research & Development figures came in at $91.0 million (Q1 2026), $98.3 million (Q4 2025), and $90.0 million (Q3 2025), per Business Quant data.